[donocco]

Nguyen

I called Novartis the makers of Affinitor. The reason they used Exemestane when the drug was first approved was that the clinical trials with Affinitor was
done on patients who were on Arimidex or Letrozole and progressed. This was
I believe was Bolero-2.

Now there is a Bolero-4 trial which did combine affinitor with Letrozole instead of Aromasin. The clinical oncologist at Novartis is going to e mail me it. From what he told me on the phone about the efficacy it may not be important which AI you use. He is going to E mail me both the Aromasin and Letrozole (with Affinitor) trials so I can visually compare the results. Ill let you know what I find.

Paul